2G Energy

(Scale All Share (Ref.), Renewables, 2GB GR)

WARBURG RESEARCH
A Münchmeyer Petersen Capital Markets Company

Buy	
EUR 80.00	(EUR 44.00)
Price	EUR 69.10
Upside	**15.8 %**

Value Indicators:	EUR
DCF:	80.00
FCF-Value Potential 2028e:	50.00

Warburg Risk Score:	**3.5**
Balance Sheet Score:	5.0
Market Liquidity Score:	2.0

Description:
Leading international manufacturer of combined heat and power plants and large heat pumps

Market Snapshot:	EUR m
Market cap:	1,239.7
No. of shares (m):	17.9
EV:	1,202.3
Freefloat MC:	680.7
Ø Trad. Vol. (30d):	3.17 m

Shareholders:	
Freefloat	54.91 %
Christian Grotholt	29.64 %
Ludger Gausling	15.45 %

Key Figures (WRe):	2025e
Beta:	1.2
Price / Book:	7.7 x
Equity Ratio:	58 %

Data centre breakthrough confirms growth case - PT raised

The **long-awaited data centre breakthrough has materialised**. 2G has **secured a low triple-digit MW order** from a confidential North American customer, representing the largest single contract in the company's history. The order comprises containerised CHP units including on-site commissioning, with deliveries spread over several years and first shipments scheduled for H2 of the current FY (WRe: late 2026 to late 2027/early 2028). The contract value translates to a roughly similar EUR amount in the low triple-digit million range, in line with the EUR 100m+ project sizes management had pointed to earlier. The materialisation of this order, combined with management's disclosure that further low triple-digit MW orders are expected within the next few months, confirms 2G's competitive positioning in the data centre vertical, provides a clear basis to lift our FY27e estimates and validates the mid-term growth potential.

FY27 guidance issued for the first time. On the back of the rapidly expanding order backlog, 2G has issued its first formal FY27 guidance, calling for **revenues of EUR 570–620m** (c. 20% growth) and an EBIT margin above 11%. The mid-point of EUR 595m comes in c. 6% above the previous WRe estimate (EUR 560m) and c. 11% above consensus (EUR 536m), with the upper end implying additional headroom. **We view the upper end of this range as the more likely scenario**, as data centre projects alone should contribute an additional c. EUR 100m in sales in FY27, while biogas, gas-fired power plants and 2G's heat pump business represent additional opportunities. Against this backdrop, available production capacity is, in our view, set to become the binding constraint rather than demand. 2G is accordingly expected to launch a further expansion of its production footprint, providing the basis for continued growth in FY28 and beyond.

Data centres are emerging as a strong growth driver. While gas turbines are already in short supply, gas engines offer advantages such as scalability and fast ramp-up/-down cycles that better match fluctuating data centre workloads. Competitor Innio (Jenbacher), one of the first movers in this market, reported 2025 order intake growth of 190% to USD 3.9bn across all markets and maintained continued strength in Q1 '26 (orders +150% to USD 1.6bn). Against this backdrop, we expect 2G to win further material contracts both during the remainder of FY26 and the coming years, **which should add a mid triple-digit EUR m amount** to the top line, underlining continued **growth of >20% and lifting group sales towards EUR 1bn towards the end of the decade**. Scale effects and positive operating leverage should support further margin expansion.

A strong uplift to mid-term growth and margin (+400bps to 15%) **assumptions lifts the PT to EUR 80.** Larger competitor Innio has also filed for its Nasdaq IPO on Tuesday. With a target valuation of c. USD 20bn, implying a >20x EBITDA multiple, the listing (scheduled before the summer break) is expected to generate positive attention for the sector. Additional orders and a Capital Markets Day scheduled for 1 October should deliver further positive news. We confirm our Buy rating.

Changes in Estimates:

FY End: 31.12. in EUR m	2025e (old)	+ / -	2026e (old)	+ / -	2027e (old)	+ / -
Sales	398.0	0.0 %	462.8	5.9 %	560.1	10.7 %
EBIT	27.0	-4.1 %	46.0	3.0 %	54.5	31.0 %

Comment on Changes:
- 2026 now expected at high-end of guidance range
- 2027 sales should reach upper guidance-end on the back of strong demand
- Capacity extension should enable continued growth in 2028



Rel. Performance vs Scale All Share	
1 month:	30.8 %
6 months:	90.6 %
Year to date:	73.2 %
Trailing 12 months:	90.2 %

Company events:	
17.06.26	FY 2025
19.08.26	AGM
29.09.26	Q2
01.10.26	CMD

FY End: 31.12. in EUR m	CAGR (24-28e)	**2022**	**2023**	**2024**	**2025e**	**2026e**	**2027e**	**2028e**
Sales	19.8 %	312.6	365.1	375.6	398.0	490.0	619.9	774.9
Change Sales yoy		17.4 %	16.8 %	2.9 %	6.0 %	23.1 %	26.5 %	25.0 %
Gross profit margin		*36.7 %*	*36.4 %*	*39.2 %*	*39.3 %*	*38.9 %*	*37.9 %*	*37.7 %*
EBITDA	27.4 %	28.7	34.6	41.2	34.3	56.6	80.2	108.7
Margin		*9.2 %*	*9.5 %*	*11.0 %*	*8.6 %*	*11.6 %*	*12.9 %*	*14.0 %*
EBIT	31.2 %	24.0	27.9	33.5	25.9	47.4	71.5	99.2
Margin		*7.7 %*	*7.7 %*	*8.9 %*	*6.5 %*	*9.7 %*	*11.5 %*	*12.8 %*
Net income	30.7 %	16.4	18.0	23.7	17.7	32.8	49.6	69.1
EPS	30.7 %	0.91	1.00	1.32	0.99	1.83	2.77	3.85
EPS adj.	30.7 %	0.91	1.00	1.32	0.99	1.83	2.77	3.85
DPS	28.2 %	0.14	0.17	0.20	0.15	0.26	0.39	0.54
Dividend Yield		0.6 %	0.7 %	0.9 %	0.2 %	0.4 %	0.6 %	0.8 %
FCFPS		-0.25	0.20	2.22	-0.86	0.89	0.84	0.95
FCF / Market cap		-1.0 %	0.8 %	9.9 %	-1.2 %	1.3 %	1.2 %	1.4 %
EV / Sales		1.4 x	1.2 x	1.0 x	3.1 x	2.5 x	1.9 x	1.5 x
EV / EBITDA		15.4 x	12.4 x	8.7 x	35.4 x	21.2 x	14.9 x	10.9 x
EV / EBIT		18.4 x	15.3 x	10.7 x	47.0 x	25.3 x	16.7 x	11.9 x
P / E		27.5 x	24.1 x	17.0 x	69.8 x	37.8 x	24.9 x	17.9 x
P / E adj.		27.5 x	24.1 x	17.0 x	69.8 x	37.8 x	24.9 x	17.9 x
FCF Potential Yield		4.9 %	5.9 %	8.9 %	2.2 %	3.5 %	4.9 %	6.7 %
Net Debt		-7.1	-4.3	-43.1	-24.1	-37.4	-47.7	-57.7
ROCE (NOPAT)		18.4 %	16.7 %	21.6 %	15.1 %	22.9 %	29.4 %	32.5 %
Guidance:	2026: Sales: EUR 440-490m (upper end); EBIT-margin: 9.5-10.5%							

Analyst
Malte Schaumann
m.schaumann@mp-capitalmarkets.com
+49 40 38022-2170

Sales development
in EUR m



Source: Warburg Research

Sales by regions
2024



Source: Warburg Research

EBIT development
in EUR m



Source: Warburg Research

Company Background

- Established in 1995, 2G Energy released its first CHP in 1996, followed by the first biogas application in 1999
- Prior to its IPO in 2007, 2G already expanded its local footprint and entered international markets with the shipping of a CHP to Japan
- After the IPO, several international subsidiaries were formed to push the further international expansion
- In 2009, natural gas CHPs were introduced to the market, establishing a key pillar for future growth. In addition, the international expansion gained traction in the US and European countries.
- After pioneering the digitization of CHPs with its unique platform in 2016, the first hydrogen CHP was introduced in 2018. In 2023, 2G Energy added large heat-pumps to its product offering.

Competitive Quality

- Founded in 1995, 2G Energy quickly positioned as technology leader for biogas CHPs in Europe. Innovative designs, best-in-class performance and quality standards improved 2G´s positioning.
- Offering a fitting solution for different client groups, 2G Energy stands out from its peer-group with its extensive product portfolio.
- Combining high quality products with an extensive service offering, 2G seeks to deliver best-in-class total cost of ownership for variing use-cases.
- Further product developments and an early move into the hydrogen CHP and large heat pump market provides for an additional competitive edge.
- Covering all integral parts of the value chain, 2G Energy is perfectly equipped to defend its market position and access growth.

EBT development
in EUR m



Source: Warburg Research

Sales by segments
2024



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period 2025e	2026e	2027e	Transitional period 2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	Term. Value
Sales	398.0	490.0	619.9	774.9	929.9	1,069.4	1,133.5	1,201.5	1,273.6	1,350.0	1,431.0	1,488.3	1,529.2	
Sales change	*6.0 %*	*23.1 %*	*26.5 %*	*25.0 %*	*20.0 %*	*15.0 %*	*6.0 %*	*6.0 %*	*6.0 %*	*6.0 %*	*6.0 %*	*4.0 %*	*2.8 %*	*2.8 %*
EBIT	25.9	47.4	71.5	96.9	125.5	160.4	170.0	180.2	191.0	202.5	214.7	223.2	229.4	
EBIT-margin	*6.5 %*	*9.7 %*	*11.5 %*	*12.5 %*	*13.5 %*	*15.0 %*	*15.0 %*	*15.0 %*	*15.0 %*	*15.0 %*	*15.0 %*	*15.0 %*	*15.0 %*	
Tax rate (EBT)	*30.3 %*	*30.1 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	*30.0 %*	
NOPAT	18.0	33.1	50.0	67.8	87.9	112.3	119.0	126.2	133.7	141.8	150.3	156.3	160.6	
Depreciation	8.4	9.2	8.8	11.6	13.9	16.0	17.0	18.0	19.1	20.3	21.5	22.3	22.9	
in % of Sales	*2.1 %*	*1.9 %*	*1.4 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	*1.5 %*	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	30.5	9.5	21.9	34.0	34.1	30.7	14.1	15.0	15.9	16.8	17.8	12.6	9.0	
- Capex	11.0	16.5	21.5	11.6	14.9	18.2	19.3	20.4	21.7	23.0	24.3	25.3	24.5	
Capex in % of Sales	*2.8 %*	*3.4 %*	*3.5 %*	*1.5 %*	*1.6 %*	*1.7 %*	*1.7 %*	*1.7 %*	*1.7 %*	*1.7 %*	*1.7 %*	*1.7 %*	*1.6 %*	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-15.0	16.3	15.4	33.8	52.8	79.5	102.6	108.8	115.3	122.2	129.6	140.7	150.0	154
PV of FCF	-16.5	16.3	14.0	28.2	40.2	55.2	65.1	63.1	61.0	59.1	57.2	56.7	55.2	838
share of PVs	**1.00 %**			**38.84 %**										**60.17 %**

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	1.00 %	Financial Strength	1.20
Cost of debt (after tax)	4.2 %	Liquidity (share)	1.30
Market return	8.25 %	Cyclicality	1.50
Risk free rate	2.75 %	Transparency	1.20
		Others	1.00
WACC	**9.52 %**	**Beta**	**1.24**

Valuation (m)

Present values 2037e	555		
Terminal Value	838		
Financial liabilities	7		
Pension liabilities	0		
Hybrid capital	0		
Minority interest	0		
Market val. of investments	0		
Liquidity	50	No. of shares (m)	17.9
Equity Value	**1,436**	**Value per share (EUR)**	**80.06**

Sensitivity Value per Share (EUR)

Beta	WACC	Terminal Growth 2.00 %	2.25 %	2.50 %	**2.75 %**	3.00 %	3.25 %	3.50 %
1.42	10.5 %	65.10	66.12	67.20	68.35	69.57	70.88	72.28
1.33	10.0 %	69.92	71.12	72.41	73.79	75.26	76.84	78.55
1.29	9.8 %	72.56	73.88	75.30	76.81	78.43	80.18	82.07
1.24	9.5 %	75.39	76.84	78.39	**80.06**	81.85	83.78	85.88
1.19	9.3 %	78.43	80.02	81.72	83.56	85.55	87.70	90.03
1.15	9.0 %	81.68	83.43	85.32	87.36	89.56	91.96	94.57
1.06	8.5 %	88.97	91.11	93.43	95.95	98.70	101.71	105.02

Beta	WACC	Delta EBIT-margin -1.5 pp	-1.0 pp	-0.5 pp	**+0.0 pp**	+0.5 pp	+1.0 pp	+1.5 pp
1.42	10.5 %	59.87	62.69	65.52	68.35	71.17	74.00	76.83
1.33	10.0 %	64.71	67.74	70.76	73.79	76.81	79.84	82.86
1.29	9.8 %	67.41	70.54	73.67	76.81	79.94	83.07	86.21
1.24	9.5 %	70.30	73.55	76.81	**80.06**	83.31	86.56	89.81
1.19	9.3 %	73.43	76.81	80.18	83.56	86.94	90.32	93.70
1.15	9.0 %	76.81	80.32	83.84	87.36	90.87	94.39	97.90
1.06	8.5 %	84.47	88.30	92.13	95.95	99.78	103.60	107.43

- As main valuation indicator, we apply our base-case DCF-valuation
- Strong growth, increasing service revenues and operating leverage boost EBIT-margin generation to c. 15%

Valuation

	2022	2023	2024	2025e	2026e	2027e	2028e
Price / Book	4.1 x	3.5 x	2.8 x	7.7 x	6.5 x	5.3 x	4.2 x
Book value per share ex intangibles	5.78	6.33	7.52	8.37	10.12	12.63	16.12
EV / Sales	1.4 x	1.2 x	1.0 x	3.1 x	2.5 x	1.9 x	1.5 x
EV / EBITDA	15.4 x	12.4 x	8.7 x	35.4 x	21.2 x	14.9 x	10.9 x
EV / EBIT	18.4 x	15.3 x	10.7 x	47.0 x	25.3 x	16.7 x	11.9 x
EV / EBIT adj.*	20.2 x	15.3 x	10.7 x	47.0 x	25.3 x	16.7 x	11.9 x
P / FCF	n.a.	119.9 x	10.1 x	n.a.	77.6 x	82.7 x	73.1 x
P / E	27.5 x	24.1 x	17.0 x	69.8 x	37.8 x	24.9 x	17.9 x
P / E adj.*	27.5 x	24.1 x	17.0 x	69.8 x	37.8 x	24.9 x	17.9 x
Dividend Yield	0.6 %	0.7 %	0.9 %	0.2 %	0.4 %	0.6 %	0.8 %
FCF Potential Yield (on market EV)	4.9 %	5.9 %	8.9 %	2.2 %	3.5 %	4.9 %	6.7 %

*Adjustments made for: -

Consolidated profit & loss

In EUR m	2022	2023	2024	2025e	2026e	2027e	2028e
Sales	**312.6**	**365.1**	**375.6**	**398.0**	**490.0**	**619.9**	**774.9**
Change Sales yoy	17.4 %	16.8 %	2.9 %	6.0 %	23.1 %	26.5 %	25.0 %
Increase / decrease in inventory	26.0	5.8	-12.3	6.9	0.0	0.0	0.0
Own work capitalised	0.2	0.2	1.6	0.8	0.5	0.0	0.0
Total Sales	**338.8**	**371.1**	**364.8**	**405.7**	**490.5**	**619.9**	**774.9**
Material expenses	224.1	238.3	217.5	249.1	299.9	385.0	482.8
Gross profit	**114.7**	**132.8**	**147.3**	**156.5**	**190.6**	**234.9**	**292.1**
Gross profit margin	*36.7 %*	*36.4 %*	*39.2 %*	*39.3 %*	*38.9 %*	*37.9 %*	*37.7 %*
Personnel expenses	57.0	64.3	73.0	84.3	90.0	101.0	120.1
Other operating income	6.2	3.1	4.6	5.1	3.0	2.3	2.5
Other operating expenses	35.3	36.9	37.7	43.0	47.0	56.0	65.9
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	**28.7**	**34.6**	**41.2**	**34.3**	**56.6**	**80.2**	**108.7**
Margin	*9.2 %*	*9.5 %*	*11.0 %*	*8.6 %*	*11.6 %*	*12.9 %*	*14.0 %*
Depreciation of fixed assets	3.7	5.0	5.1	5.8	6.4	7.0	7.5
EBITA	**24.9**	**29.6**	**36.1**	**28.6**	**50.2**	**73.2**	**101.2**
Amortisation of intangible assets	0.9	1.7	2.6	2.7	2.8	1.7	2.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	**24.0**	**27.9**	**33.5**	**25.9**	**47.4**	**71.5**	**99.2**
Margin	*7.7 %*	*7.7 %*	*8.9 %*	*6.5 %*	*9.7 %*	*11.5 %*	*12.8 %*
EBIT adj.	**21.9**	**27.9**	**33.5**	**25.9**	**47.4**	**71.5**	**99.2**
Interest income	0.1	0.1	0.2	0.0	0.0	0.0	0.0
Interest expenses	0.4	0.6	0.7	0.5	0.5	0.5	0.5
Other financial income (loss)	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0
EBT	**23.6**	**27.3**	**33.0**	**25.4**	**46.9**	**70.9**	**98.7**
Margin	*7.5 %*	*7.5 %*	*8.8 %*	*6.4 %*	*9.6 %*	*11.4 %*	*12.7 %*
Total taxes	7.2	9.3	9.3	7.7	14.1	21.3	29.6
Net income from continuing operations	**16.4**	**18.0**	**23.7**	**17.7**	**32.8**	**49.6**	**69.1**
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	**16.4**	**18.0**	**23.7**	**17.7**	**32.8**	**49.6**	**69.1**
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	**16.4**	**18.0**	**23.7**	**17.7**	**32.8**	**49.6**	**69.1**
Margin	*5.2 %*	*4.9 %*	*6.3 %*	*4.4 %*	*6.7 %*	*8.0 %*	*8.9 %*
Number of shares, average	17.9	17.9	17.9	17.9	17.9	17.9	17.9
EPS	**0.91**	**1.00**	**1.32**	**0.99**	**1.83**	**2.77**	**3.85**
EPS adj.	0.91	1.00	1.32	0.99	1.83	2.77	3.85

*Adjustments made for:

Guidance: 2026: Sales: EUR 440-490m (upper end); EBIT-margin: 9.5-10.5%

Financial Ratios

	2022	2023	2024	2025e	2026e	2027e	2028e
Total Operating Costs / Sales	99.2 %	92.2 %	86.2 %	93.3 %	88.5 %	87.1 %	86.0 %
Operating Leverage	1.9 x	1.0 x	6.9 x	-3.8 x	3.6 x	1.9 x	1.6 x
EBITDA / Interest expenses	74.7 x	55.8 x	56.2 x	66.4 x	109.5 x	155.1 x	217.3 x
Tax rate (EBT)	30.6 %	34.0 %	28.3 %	30.3 %	30.1 %	30.0 %	30.0 %
Dividend Payout Ratio	15.3 %	16.9 %	15.2 %	15.2 %	14.2 %	14.1 %	14.0 %
Sales per Employee	371,291	386,758	373,731	n.a.	n.a.	n.a.	n.a.

Sales, EBITDA
in EUR m



Source: Warburg Research

Operating Performance
in %



Source: Warburg Research

Performance per Share



Source: Warburg Research

Consolidated balance sheet

In EUR m	2022	2023	2024	2025e	2026e	2027e	2028e
Assets							
Goodwill and other intangible assets	5.0	10.3	11.3	10.1	8.9	8.6	8.1
thereof other intangible assets	1.1	1.0	0.8	5.4	4.1	3.9	3.4
thereof Goodwill	3.0	6.9	4.8	4.8	4.8	4.8	4.8
Property, plant and equipment	26.8	28.4	48.5	52.3	60.9	73.9	77.4
Financial assets	0.1	0.1	0.2	0.2	0.2	0.2	0.2
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	**31.9**	**38.7**	**60.0**	**62.6**	**69.9**	**82.7**	**85.7**
Inventories	102.6	109.8	88.7	99.5	122.5	155.0	193.7
Accounts receivable	57.1	58.5	68.7	70.9	85.9	108.7	135.9
Liquid assets	13.5	12.6	50.0	31.0	44.3	54.6	64.6
Other short-term assets	6.5	7.8	11.0	11.0	11.0	11.0	11.0
Current assets	**179.7**	**188.7**	**218.4**	**212.4**	**263.7**	**329.3**	**405.2**
Total Assets	**211.6**	**227.4**	**278.5**	**275.0**	**333.6**	**411.9**	**490.8**
Liabilities and shareholders' equity							
Subscribed capital	17.9	17.9	17.9	17.9	17.9	17.9	17.9
Capital reserve	3.0	3.0	3.0	3.0	3.0	3.0	3.0
Retained earnings	88.5	103.9	124.5	138.6	168.7	213.7	275.7
Other equity components	-0.7	-0.9	0.7	0.7	0.7	0.6	0.7
Shareholders' equity	108.7	123.9	146.2	160.3	190.4	235.2	297.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	**108.6**	**123.9**	**146.2**	**160.3**	**190.4**	**235.3**	**297.4**
Provisions	21.4	24.4	24.4	24.4	24.4	24.4	24.4
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	6.3	8.3	6.9	6.9	6.9	6.9	6.9
Short-term financial liabilities	2.5	2.7	2.5	2.5	2.5	2.5	2.5
Accounts payable	20.5	17.1	9.5	15.3	18.8	27.2	34.0
Other liabilities	54.7	53.7	91.5	68.1	93.1	118.1	128.1
Liabilities	**103.0**	**103.5**	**132.3**	**114.7**	**143.2**	**176.6**	**193.4**
Total liabilities and shareholders' equity	**211.6**	**227.4**	**278.5**	**275.0**	**333.6**	**411.9**	**490.8**

Financial Ratios

	2022	2023	2024	2025e	2026e	2027e	2028e
Efficiency of Capital Employment							
Operating Assets Turnover	2.6 x	2.6 x	3.1 x	2.5 x	2.8 x	2.9 x	2.9 x
Capital Employed Turnover	3.1 x	3.1 x	3.6 x	2.9 x	3.2 x	3.3 x	3.2 x
ROA	51.4 %	46.4 %	39.4 %	28.3 %	46.9 %	60.0 %	80.6 %
Return on Capital							
ROCE (NOPAT)	18.4 %	16.7 %	21.6 %	15.1 %	22.9 %	29.4 %	32.5 %
ROE	16.1 %	15.5 %	17.5 %	11.5 %	18.7 %	23.3 %	25.9 %
Adj. ROE	16.1 %	15.5 %	17.5 %	11.5 %	18.7 %	23.3 %	25.9 %
Balance sheet quality							
Net Debt	-7.1	-4.3	-43.1	-24.1	-37.4	-47.7	-57.7
Net Financial Debt	-7.1	-4.3	-43.1	-24.1	-37.4	-47.7	-57.7
Net Gearing	-6.6 %	-3.4 %	-29.5 %	-15.0 %	-19.6 %	-20.3 %	-19.4 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	6.1	6.9	8.1	8.9	10.6	13.1	16.6
Book value per share ex intangibles	5.8	6.3	7.5	8.4	10.1	12.6	16.1

ROCE Development



Source: Warburg Research

Net debt

in EUR m



Source: Warburg Research

Book Value per Share

in EUR



Source: Warburg Research

Consolidated cash flow statement

In EUR m	2022	2023	2024	2025e	2026e	2027e	2028e
Net income	16.4	18.0	23.7	17.7	32.8	49.6	69.1
Depreciation of fixed assets	3.7	5.0	5.1	5.8	6.4	7.0	7.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.9	1.7	2.6	2.7	2.8	1.7	2.0
Increase/decrease in long-term provisions	3.4	-1.5	2.7	0.0	0.0	0.0	0.0
Other non-cash income and expenses	2.3	4.9	-0.4	0.0	0.0	0.0	0.0
Cash Flow before NWC change	**26.7**	**28.0**	**33.7**	**26.1**	**42.0**	**58.4**	**78.6**
Increase / decrease in inventory	-17.2	-11.1	37.2	-10.8	-23.0	-32.5	-38.7
Increase / decrease in accounts receivable	-13.4	-1.2	-10.2	-2.2	-15.0	-22.8	-27.2
Increase / decrease in accounts payable	8.9	-3.9	-7.3	-17.6	28.5	33.4	16.8
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-21.7	-16.3	19.6	-30.5	-9.5	-21.9	-49.1
Net cash provided by operating activities [1]	**4.9**	**11.8**	**53.4**	**-4.4**	**32.5**	**36.5**	**29.5**
Investments in intangible assets	-1.2	-1.4	-3.8	-1.5	-1.5	-1.5	-1.5
Investments in property, plant and equipment	-8.2	-6.7	-9.7	-9.5	-15.0	-20.0	-11.0
Payments for acquisitions	-0.8	-3.5	-0.6	0.0	0.0	0.0	0.0
Financial investments	0.0	-0.1	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.5	0.2	0.7	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	**-9.8**	**-11.4**	**-11.5**	**-11.0**	**-16.5**	**-21.5**	**-12.5**
Change in financial liabilities	1.0	1.9	-1.6	0.0	0.0	0.0	0.0
Dividends paid	-2.2	-2.5	-3.0	-3.6	-2.7	-4.7	-7.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	**-1.6**	**-1.2**	**-5.4**	**-3.6**	**-2.7**	**-4.7**	**-7.0**
Change in liquid funds [1]+[2]+[3]	**-6.4**	**-0.9**	**36.4**	**-19.0**	**13.3**	**10.3**	**10.0**
Effects of exchange-rate changes on cash	-0.1	-0.1	0.8	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	13.1	12.3	49.5	31.0	44.3	54.6	64.6

Financial Ratios

	2022	2023	2024	2025e	2026e	2027e	2028e
Cash Flow							
FCF	-4.4	3.6	39.8	-15.4	16.0	15.0	17.0
Free Cash Flow / Sales	-1.4 %	1.0 %	10.6 %	-3.9 %	3.3 %	2.4 %	2.2 %
Free Cash Flow Potential	21.4	25.3	31.9	26.7	42.5	58.9	79.1
Free Cash Flow / Net Profit	-27.0 %	20.0 %	168.2 %	-87.0 %	48.7 %	30.2 %	24.6 %
Interest Received / Avg. Cash	0.5 %	0.4 %	0.7 %	0.0 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	6.6 %	8.5 %	9.7 %	7.5 %	7.5 %	7.5 %	7.2 %
Management of Funds							
Investment ratio	3.0 %	2.2 %	3.6 %	2.8 %	3.4 %	3.5 %	1.6 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	200.6 %	122.5 %	175.1 %	130.2 %	179.7 %	245.4 %	131.6 %
Avg. Working Capital / Sales	26.7 %	28.1 %	24.7 %	22.6 %	22.4 %	20.3 %	20.8 %
Trade Debtors / Trade Creditors	278.8 %	342.6 %	725.9 %	463.4 %	456.9 %	399.6 %	399.7 %
Inventory Turnover	2.2 x	2.2 x	2.5 x	2.5 x	2.4 x	2.5 x	2.5 x
Receivables collection period (days)	67	59	67	65	64	64	64
Payables payment period (days)	33	26	16	22	23	26	26
Cash conversion cycle (Days)	128	139	77	115	99	90	102

CAPEX and Cash Flow

in EUR m



Source: Warburg Research

Free Cash Flow Generation



Source: Warburg Research

Working Capital

Source: Warburg Research

LEGAL DISCLAIMER

This research report (“investment recommendation”) was prepared by the Warburg Research GmbH and is passed on by the Münchmeyer Petersen Capital Markets GmbH. Warburg Research GmbH since December 1, 2025 is a fully owned subsidiary of the Münchmeyer Petersen Capital Markets GmbH (MPCM). This research report is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of MPCM or Warburg Research GmbH for damages of any kind whatsoever, and MPCM and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither MPCM nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. MPCM and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of MPCM and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, MPCM and Warburg Research GmbH are liable for normal negligence. In any case, the liability of MPCM and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of MPCM, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst’s personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the respective company analysed is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also https://disclaimer.mp-capitalmarkets.com/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst’s assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company’s products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

The respective commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from MPCM and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH or MPCM do not receive a gratuity – directly or indirectly – from the investment banking activities of MPCM, MPC Münchmeyer Petersen & Co. GmbH or affiliated companies.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

Warburg Research GmbH is subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, wholly owned by MPCM, Germany. Warburg Research GmbH or MPCM is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Crédit Industriel et Commercial (CIC) and MPCM have concluded a Research Distribution Agreement that gives CIC Market Solutions Inc. exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

-1-	Warburg Research GmbH, MPCM, or an affiliated company according to Section 271 (2) of the German Commercial Code (HGB) (affiliated companies), or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
-2-	Within the last twelve months affiliated companies participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
-3-	Affiliated companies **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
-4-	Affiliated companies reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
-5-	The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
-6a-	Affiliated companies hold a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
-6b-	Affiliated companies hold a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
-6c-	The issuer holds shares of more than 5% of the total issued capital of an affiliated company.
-7-	The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
2G Energy	5	https://disclaimer.mp-capitalmarkets.com/disclaimer_en/DE000A0HL8N9.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	**Buy:**	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	**Hold:**	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	**Sell:**	The price of the analysed financial instrument is expected to fall over the next 12 months.
"-"	**Rating suspended:**	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	132	72
Hold	41	22
Sell	5	3
Rating suspended	6	3
Total	**184**	**100**

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING …

… taking into account only those companies for which affiliated companies provided major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	2	100
Hold	0	0
Sell	0	0
Rating suspended	0	0
Total	**2**	**100**

PRICE AND RATING HISTORY 2G ENERGY AS OF 27.05.2026

Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Ebbi Attarzadeh	+49 40 38022-1236 e.attarzadeh@mp-capitalmarkets.com		

RESEARCH

Henner Rüschmeier Head of Research	+49 40 38022-2270 h.rueschmeier@mp-capitalmarkets.com	**Oliver Schwarz** Chemicals, Agriculture	+49 40 38022-2250 o.schwarz@mp-capitalmarkets.com
Stefan Augustin Cap. Goods, Engineering	+49 40 38022-2168 s.augustin@mp-capitalmarkets.com	**Yannik Siering** Software & IT Services	+49 40 38022-1240 y.siering@mp-capitalmarkets.com
Christian Cohrs Industrials & Transportation	+49 40 38022-2175 c.cohrs@mp-capitalmarkets.com	**Sebastian Ubert** Cap. Goods, Engineering	+49 40 38022-1252 s.ubert@mp-capitalmarkets.com
Felix Ellmann Software, IT	+49 40 38022-2120 f.ellmann@mp-capitalmarkets.com		
Philipp Kaiser Real Estate, Construction	+49 40 38022-2260 p.kaiser@mp-capitalmarkets.com		
Andreas Pläsier Banks, Financial Services	+49 40 38022-2246 a.plaesier@mp-capitalmarkets.com		
Malte Schaumann Technology	+49 40 38022-2170 m.schaumann@mp-capitalmarkets.com		

INSTITUTIONAL EQUITY SALES

Michael Grohmann Head of Equity Sales	+49 40 38022-1238 m.grohmann@mp-capitalmarkets.com		
Ebbi Attarzadeh Sales	+49 40 38022-1236 e.attarzadeh@mp-capitalmarkets.com	**Leyan Ilkbahar** Roadshow/Marketing	+49 40 38022-1247 l.ilkbahar@mp-capitalmarkets.com
Olaf Gabriel Sales	+49 40 38022-1239 o.gabriel@mp-capitalmarkets.com	**Antonia Möller** Roadshow/Marketing	+49 40 38022-1248 a.moeller@mp-capitalmarkets.com

SALES TRADING

Bastian Quast	+49 40 38022-1242 b.quast@mp-capitalmarkets.com		

Our research can be found under:

MPCM | Warburg Research	research.mp-capitalmarkets.com	LSEG	www.lseg.com
Bloomberg	ERH MPC	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		

For access please contact:

Antonia Möller Sales Assistance	+49 40 38022-1248 a.moeller@mp-capitalmarkets.com